tists working on cord blood transplantation and banking. The first section of the guidelines consists of procedures for PBC collection, processing kryopreservation, virus screening, informed consent form, etc. The second section includes disease indications for PCB transplantation. Since the new study group for PCB transplantation was organized in the Research Group for Hematopoietic Cell Transplantation and Immune Response in 1997 (Chairperson I. Kodera), the registration of patients and cord blood units of HLA stocked in local cord blood banks has been attempted. For that purpose each local bank was audited by auditors selected by the members following the guidelines and FA AT audit manual during the period from December 1997 through February 1998. Because of the increase of PCB transplantation and public opinion motivatd by a volunteer group that requested the health insurance coverage for PCB transplantationand the establishment of a public PCB Bank, the MHW moved to cover PCB transplantation in the national health insurance program beginning April this year. Simultaneously, a PCB Examination Association was organized by the MHW. It is composed of members representing local cord blood banks, transplant specialists, gynecologists, nurses, jurists and volunteers. etc. The working group for the Association proposed national guidelines for PCB processing and transplantation, and standard manuals based on the previously mentioned guidelines. The Association made an interim report in July; the PCB Central Connection Association will be composed of approved local cord blood banks and an Audit Organization, and will be independent of the Bone Marrow Registry of Japan. The local PCB banks will work under the same guidelines to insure the quality of PCB and create a network for the fast supply of PCB. Ex vivo expansion of human umbilical cord blood (UCB) seems to be an intriguing way to overcome the main limiting factor to use UCB in the adult transplant setting, i.e. the small number of progenitor cells available. We compared the MNC fraction from UCB with CD34+ selected cells in a static culture system using serum free medium supplemented with defined cytokines. Total cell number expansion of MNC was inferior to CD34+ selected cells (1.6 fold at day 7 for MNC fraction versus 7 fold for CD34+ fraction). However, within the MNC fraction CD34+ cell pool was expanded from 0.94% at day 0 to 5.8% at day 7, whereas in the CD34+ selected fraction CD34+ cell content declined from 62.2% at day 0 to 27.7% at day 7. The overall number of CD34+ cells then decreased from 10.5 fold at day 7 to 5.3 fold at day14 in the cultured MNC, and remained stable at 2.3 fold from day 7 to day 4 in the CD34+ selected fraction.The number of CFU-GM increased during culture of both the MNC as well as CD34+ selected cells: 16.7 fold CFU-GM proliferation at day 7 for MNC and 11.3 fold proliferation for CD34+ selected cells, respectively. Interestingly, the expansion of the C34+ cells in the MNC fraction was at least in part attributable to T cells, since physical abrogation of T cells blocked this effect (11.5 fold increase at day 7 without T cell depletion versus 5.1 fold only with T cell depletion. Refeeding and reseeding of cells at day 7 had stimulating effects in particular on the CD34+ cells where cell number increased from 16.3 fold to 58.1 fold at day 14. Since the safe clinical use of ex vivo manipulated UCB requires a genetically intact graft even after extensive cytokine stimulation, we assessed cultured UCB samples by means of conventional cytogenetic analysis (G-banding). We could find sporadic chromosomal aberrations in 4 out of 100 metaphases examined after 7-20 days of ex vivo expansion. Before ex vivo expanded UCB may enter clinical transplant protocols, this finding needs further exploration in larger series.
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Short time culturing leading to CD34+ expansion in UCB appears to be possible. However, large scale systems remain to be developed to provide sufficient cell numbers for UCB transplants in adult patients.
S11e: Two Conflicting Concepts of Cord Blood Banking
E. Lampeter, D. Egger. VITA 34, Gesellschaft für Zelltransplantate mbH, Nonnenstraße 37, 04229 Leipzig, Germany
Individual cord blood banking for the child or a family member and cord blood banking for use as an unrelated transplant in cancer therapy is currently discussed predominantly in the context of leukemia therapy. However, only about thirty percent of all haematopoietic stem cell transplantations in Europe in 1996 were allogeneic transplantations and only a part of them (6% of all) were performed with unrelated cells. In contrast, 70 percent of transplantations in 1996 were performed with autologous patientderived cells. This may be a most interesting area of autologous cord blood application because these cells have been harvested from healthy individuals. Moreover, in 25 percent of allogeneic graft recipients the availability of matched sibling-derived cord blood can be anticipated, provided that cord blood has been individually banked. As shown by Gluckman et al. (NEJM, 337: 373-381, 1997) 12 month overall survival probability after cord blood transplantations from related donors was significantly (63% vs. 29%; P Ͻ 0.001) higher compared to those from unrelated donors. Hence, a better outcome of intra-familiar cord blood transplantation has been shown and a better outcome in autologous cord blood transplantation compared to autologous bone marrow or peripheral blood progenitor cell transplantations could be expected based on the assumption that the grafts are not contaminated with tumor cells. The main problem in autologous cord blood transplantation seems to be how to perform clinical trials. Obviously,
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no clinical trials can be performed without individually frozen cord blood samples. Allthough it may take decades before significant numbers of transplantations have been carried out, this alone is not reason enough to conclude that there is no need for autologous cord blood.
Furthermore, individually banked cord blood might be rather more than a source of haematopoietic stem cells. Even if this is speculative at present, it has to be taken into consideration in clients' interest by individual cord blood banks where cord blood remains the property of the family. This is a key difference between individual and public cord blood banking.
The question of Jodi K. Fredrickson: "Umbilical cord blood stem cells: My body makes them, but do I get to keep them?", discussed in the Journal of Contemporary Health Law and Policy (14: 477-502, 1998) illustrates another point of discussion in the field of cord blood banking.
The theory that organs and tissues are personal property over which each person should have dispositional control is still in its formative years. However, sentences like: "It is generally agreed that cord and placental blood is a discarded product and can be used without asking permission. . ." (Gluckman et al., Bone Marrow Transplantation 22 (Suppl. 1), 1998) disregard the present discussion on property rights of the child and seems not to be appropriate any longer.
Hence, legal regulations are in demand as soon as possible to facilitate cord blood banking for both intra-familiar as well as for public use. Even now it is obvious that women who decide to save their children's umbilical cord blood are going to participate in recent and in future scientific progress. Despite all controversy, both concepts have the same basic idea: umbilical cord blood is too valuable to be discarded.
